Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

Figures & data

Table 1 Cohort 1 (N=131): Clinical Characteristics and Maintenance Medication in the Past at Entry into the GAN Registry, ie, Before Starting Mepolizumab Therapy

Baseline characteristics (N=131*)
Exacerbations during the past 12 months	n	%
Never	4	3.1
1× peryear	10	7.6
>1× per year but <1× per month	83	63.4
≥1× per month	28	21.4
Unknown	6	4.6
GINA control status
Controlled	3	2.3
Partly controlled	11	8.4
Uncontrolled	117	89.3
Systemic steroids/OCS as maintenance medication	72	55.0
Lung function, pre-bronchodilator	Mean (±SD)
FEV1, liter (N=104)	2.70 (±7.44)
FEV1, % (N=105)	65.1 (±24.9)
Eosinophils, cells/μL (N=107)	500 (±438)
Leukocytes, cells/nL (N=108)	8.6 (±2.5)

Note: *Unless otherwise stated.

Abbreviations: GINA, Global Initiative for Asthma; OCS, oral corticosteroids.

Table 2 Cohort 1: Clinical Characteristics in the Subset of Patients (N=87) with Available 4-Month Follow-Up Data After Initiating Mepolizumab Therapy

	Baseline	After 4-Month FU
GINA control status (N=87)*	n (%)
Controlled	3 (3.4)	21 (24.1)
Partly controlled	6 (6.9)	27 (31.0)
Uncontrolled	78 (89.7)	39 (44.8)
Systemic steroids/OCS as maintenance medication (N=87)*	47 (54.0)	33 (37.9)
Lung Function (N=66), Pre-Bronchodilator*	Mean (±SD)		Difference to Baseline	p-value
FEV1, liter	3.21 (±9.27)	3.42 (±9.49)	0.21	0.0088
FEV1, %	68.4 (±23.6)	74.8 (±24.4)	6.4	0.0030
Eosinophils (N=52), cells/μL*	534.8 (±420.1)	89.1 (±83.8)	−445.7	<0.0001
Leukocytes, cells/nL	8.7 (±2.5)	7.5 (±2.6)	−1.3	0.0010

Note: *Patients with available data.

Abbreviations: FU, follow-up; GINA, Global Initiative for Asthma; OCS, oral corticosteroids.

Table 3 Cohort 2 (N=220): Asthma Symptoms, Other Allergic Conditions/Comorbidities, and Rescue Medication at Entry into the GAN Registry

Asthma symptoms	n	%*
Total number of patients with symptoms	192	87.3**
Dyspnea	159	82.8
Exertional dyspnea	157	81.8
Resting dyspnea	23	12.0
Chest tightness/chest pain	43	22.4
Coughing	125	65.1
Rhonchus or wheezing	79	41.1
Prolonged expiration	18	9.4
Reduced exercise capacity	138	71.9
Bronchial hyperresponsiveness (BHR)	129	67.2
Symptoms during the day	n	%*
Never	5	2.6
≤2× per week	48	25.0
>2× per week but <1× per day	46	24.0
≥1× per day	80	41.7
Unknown	13	6.8
Symptoms during the night	n	%*
Never	52	27.1
≤2× per month	37	19.3
>2× per month but <1× per week	24	12.5
≥1 time per week	29	15.1
Common nocturnal symptoms	44	22.9
Unknown	6	3.1
Allergic condition/Comorbidity (patients with available data)	n	%
Allergic rhinitis/rhinoconjunctivitis	101 (220)	45.9
Food allergy	39 (220)	17.7
Atopic eczema	12 (220)	5.5
Other allergic conditions	21 (220)	9.5
Chronic sinusitis	134 (219)	61.2
Nasal polyps	67 (153)	43.8
Frequent LRTI (>2× per year)	133 (219)	60.7
GERD	73 (219)	33.3
Asthma rescue medication	n	%**
Never	62	28.2
≤2× per week	53	24.1
>2× per week but <1× per day	42	19.1
≥1× per day	54	24.5
Unknown	9	4.1

Notes: *Of total number of patients with symptoms (n=192). **Of total cohort population (N=220).

Abbreviations: GERD, gastroesophageal reflux disease; LRTI, lower respiratory tract infection.

Figure 1 Cohort 2: Percentage of patients with symptoms (a) during the day or (b) during the night in the subset of patients with available 1-year follow-up data after entry into the GAN registry (N=80 and N=79 with available data).

Abbreviation: FU, follow-up.

Table 4 Cohort 2: Lung Function and Symptom Control in the Subset of Patients (N=89) with Available 1-Year Follow-Up Data After Entry into the GAN Registry

	At Entry Into Registry	After 1-Year FU	Difference to Entry	p-value
Lung function pre-bronchodilator, mean (±SD)
FEV1, liter N=57*	2.09 (±0.89)	2.13 (±0.91)	0.05	0.5020
FEV1, % N=56*	71.36 (±24.77)	73.68 (±26.84)	2.32	0.3106
FEV1/FVC N=56*	67.93 (±16.64)	68.74 (±15.54)	0.81	0.5165
PEF, liter per second	5.51 (±2.22)	5.67 (±2.54)	1.66	0.4766
Symptom control mean (±SD) points
ACQ-5 N=66*	1.78 (±1.41)	1.75 (±1.54)	−0.03	0.8818
ACT N=71*	18.5 (±5.2)	18.6 (±5.6)	0.0	0.9823
Mini AQLQ N=63*	4.75 (±1.43)	5.04 (±1.38)	0.29	0.0876

Note: *Patients with available data.

Abbreviations: ACQ-5, Asthma Control Questionnaire, 5-item version; ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; FEV₁, forced expiratory volume in 1 second; FU, follow-up; FVC, forced vital capacity; PEF, peak expiratory flow; SD, standard deviation.